Blog
RSS FeedPosted by Michael Wonder on 12 Jun 2023
One stop shop for AI and digital regulations for health and social care launched
12 June 2023 - A new online advice service to help the NHS and wider care system adopt and make ...
Posted by Michael Wonder on 07 Jun 2023
Bulevirtide acetate for the treatment of adults with chronic hepatitis D (final guidance)
7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
New drugs pilot to tackle obesity and cut NHS waiting lists
7 June 2023 - More people living with obesity will have access to the newest and most effective obesity drugs to ...
Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma
7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of ...
Posted by Michael Wonder on 06 Jun 2023
Esketamine hydrochloride for the treatment of adults with major depressive disorder at imminent risk of suicide
6 June 2023 - NICE is unable to make a recommendation on the use of esketamine hydrochloride (Spravato) for the treatment ...
Posted by Michael Wonder on 06 Jun 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone ...
Posted by Michael Wonder on 02 Jun 2023
First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use
2 June 2023 - NICE’s final draft guidance recommends mavacamten (Camzyos, Bristol-Myers Squibb) as an add-on to standard care that ...
Posted by Michael Wonder on 02 Jun 2023
Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor symptoms
31 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Jun 2023
Mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma
31 May 2023 - NICE has published evidence based recommendations on the use of mosunetuzumab (Lunsumio) for the treatment of ...
Posted by Michael Wonder on 31 May 2023
Ibrutinib and venetoclax for untreated chronic lymphocytic leukaemia
31 May 2023 - NICE has published evidence-based recommendations on the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclyxto) ...
Posted by Michael Wonder on 31 May 2023
145,000 people in England to have further treatment choice for preventing migraine attacks
31 May 2023 - NICE has for the first time recommended an oral treatment for preventing migraines. ...
Posted by Michael Wonder on 30 May 2023
Family seek to raise money for lung cancer drug
29 May 2023 - A family has raised £12,000 to pay for a cancer drug for their mother, which was ...
Posted by Michael Wonder on 29 May 2023
NICE welcomes life sciences review recommendations
26 May 2023 - NICE’s priority is to get the best care to patients fast while ensuring value for the ...
Posted by Michael Wonder on 23 May 2023
Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...